OncoCyte Free Cash Flow Per Share 2014-2024 | OCX

OncoCyte free cash flow per share from 2014 to 2024. Free cash flow per share can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis

OncoCyte Free Cash Flow Per Share 2014-2024 | OCX

OncoCyte free cash flow per share from 2014 to 2024. Free cash flow per share can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$84.8B
Cencora (COR)$43.4B
DiDi Global (DIDIY)$23B
Natera (NTRA)$21.2B
ICON (ICLR)$17.5B
Viatris (VTRS)$14.8B
Avantor (AVTR)$14.4B
Revvity (RVTY)$13.6B
BioMerieux (BMXMF)$12.3B
CochLear (CHEOY)$11.9B
Solventum (SOLV)$11.4B
Medpace Holdings (MEDP)$10.4B
Doximity (DOCS)$10B
Charles River Laboratories (CRL)$9.3B
HealthEquity (HQY)$8.4B
Sonic Healthcare (SKHHY)$8.1B
Bausch + Lomb (BLCO)$6.3B
Amplifon S.p.A (AMFPF)$5.9B
Sotera Health (SHC)$3.9B
Organon (OGN)$3.9B
BrightSpring Health Services (BTSG)$3B
Surgery Partners (SGRY)$2.7B
Concentras Parent (CON)$2.5B
Ardent Health Partners (ARDT)$2.4B
Alignment Healthcare (ALHC)$2.2B
GeneDx Holdings (WGS)$2.2B
Premier (PINC)$2.1B
PACS (PACS)$2B
GoodRx Holdings (GDRX)$1.7B
Ryman Healthcare (RYHTY)$1.7B